8121
-
Drug, Healthcare and Patient Safety
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Real benefits for authors, including fast-track processing of papers.
Drug, Healthcare and Patient Safety
(176,340) Views
Editor in Chief Professor Shufeng Zhou
1179-1365
ReviewTNF-α inhibitors: are they carcinogenic?
αGirindra Raval, Paulette Mehta
Drug, Healthcare and Patient Safety 2010, 2:241-247
06 December 2010
Review
Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
Paul A Gurbel, Udaya S Tantry, Dean J Kereiakes
Drug, Healthcare and Patient Safety 2010, 2:233-240
15 November 2010
Original Research
Insomnia medication use and the probability of an accidental event in an older adult population
Alon Y Avidan, Liisa A Palmer, Justin F Doan, et al
Drug, Healthcare and Patient Safety 2010, 2:225-232
12 November 2010
Review
Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
Kitty Poon, Allen B King
Drug, Healthcare and Patient Safety 2010, 2:213-223
28 October 2010
Review
Safety and tolerability of antipsychotics: focus on amisulpride
Mario F Juruena, Eduardo Pondé de Sena, Irismar Reis de Oliveira
Drug, Healthcare and Patient Safety 2010, 2:205-211
01 October 2010
Review
Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin
Harald Vonkeman, Inger Meek, Mart van de Laar
Drug, Healthcare and Patient Safety 2010, 2:191-204
06 October 2010
Review
Antiepileptic drugs and suicidality
Jeffery W Britton, Jerry J Shih
Drug, Healthcare and Patient Safety 2010, 2:181-189
28 September 2010
Review
Safety and clinical efficacy of golimumab in the treatment of arthritides
Ismail Simsek, Yusuf Yazici
Drug, Healthcare and Patient Safety 2010, 2:169-180
28 September 2010
Case report
Profound thrombocytopenia after primary exposure to eptifibatide
Nicholas B Norgard, Brian T Badgley
Drug, Healthcare and Patient Safety 2010, 2:163-167
21 September 2010
Review
Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy
Mitchell S Buckley, Robin L Staib, Laura M Wicks, et al
Drug, Healthcare and Patient Safety 2010, 2:151-161
20 September 2010
Review
Antidepressant-associated sexual dysfunction: impact, effects, and treatment
Agnes Higgins, Michael Nash, Aileen M Lynch
Drug, Healthcare and Patient Safety 2010, 2:141-150
09 September 2010
Case report
A danger of induction of Brugada syndrome during pill-in-the-pocket therapy for paroxysmal atrial fibrillation
Yoshiyasu Aizawa, Tomohiro Matsuhashi, Toshiaki Sato, et al
Drug, Healthcare and Patient Safety 2010, 2:139-140
25 August 2010
Review
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
Luca Dalle Carbonare, Mirko Zanatta, Adriano Gasparetto, et al
Drug, Healthcare and Patient Safety 2010, 2:121-137
19 August 2010
Review
Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations
Sarah Horton, Maya H Buch, Paul Emery
Drug, Healthcare and Patient Safety 2010, 2:101-119
17 August 2010
Original Research
Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital
Rajakannan Thiyagu, Surulivel R Mallayasamy, Valakkathala Rajesh, et al
Drug, Healthcare and Patient Safety 2010, 2:95-100
30 June 2010
Other
Incorrect description of mode of excretion of linagliptin
Hans-Juergen Woerle, Sanjay Patel
Drug, Healthcare and Patient Safety 2010, 2:93-94
02 June 2010
Review
Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
Rohan Shahani, Kevin G Kwan, Anil Kapoor
Drug, Healthcare and Patient Safety 2010, 2:85-91
28 June 2010
Review
Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension
Parul Ichhpujani, L Jay Katz
Drug, Healthcare and Patient Safety 2010, 2:73-83
24 May 2010
Review
Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
Adie Viljoen, Anthony S Wierzbicki
Drug, Healthcare and Patient Safety 2010, 2:61-71
24 May 2010
Review
Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options
Juraj Payer, Kristina Brazdilova, Peter Jackuliak
Drug, Healthcare and Patient Safety 2010, 2:49-59
20 May 2010
Review
Preclinical pharmacology, efficacy, and safety of varenicline in smoking cessation and clinical utility in high risk patients
Zheng-Xiong Xi
Drug, Healthcare and Patient Safety 2010, 2:39-48
14 April 2010
Review
Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections
Dionissios Neofytos, Edina Avdic, Anna-Pelagia Magiorakos
Drug, Healthcare and Patient Safety 2010, 2:27-38
20 April 2010
Original Research
Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers
Elisabet Ekman, Staffan Hägg, Anders Sundström, et al
Drug, Healthcare and Patient Safety 2010, 2:21-25
29 March 2010
Review
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
Mary Elizabeth Cox, Jennifer Rowell, Leonor Corsino, et al
Drug, Healthcare and Patient Safety 2010, 2:7-19
28 January 2010
Mini-review
Beyond the black box: drug- and device-associated hypersensitivity events
Charles L Bennett, Olatokunbo S Adegboro, Elizabeth A Calhoun, Dennis Raisch
Drug, Healthcare and Patient Safety 2010, 2:1-5
16 February 2010
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
